Immix Biopharma (IMMX) Competitors

Design Therapeutics (NASDAQ:DSGN) and Immix Biopharma (NASDAQ:IMMX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, media sentiment, community ranking, risk, profitability, valuation and earnings.

Does the media refer more to DSGN or IMMX?

In the previous week, Design Therapeutics had 2 more articles in the media than Immix Biopharma. MarketBeat recorded 3 mentions for Design Therapeutics and 1 mentions for Immix Biopharma. Immix Biopharma's average media sentiment score of 1.90 beat Design Therapeutics' score of 0.32 indicating that Immix Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Design Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Immix Biopharma	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Which has more risk & volatility, DSGN or IMMX?

Design Therapeutics has a beta of 1.82, indicating that its stock price is 82% more volatile than the S&P 500. Comparatively, Immix Biopharma has a beta of 0.27, indicating that its stock price is 73% less volatile than the S&P 500.

Which has higher earnings and valuation, DSGN or IMMX?

Design Therapeutics is trading at a lower price-to-earnings ratio than Immix Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Design Therapeutics	N/A	N/A	-$66.86M	-$0.85	-5.95
Immix Biopharma	N/A	N/A	-$15.43M	-$0.85	-2.40

Is DSGN or IMMX more profitable?

Design Therapeutics' return on equity of -18.01% beat Immix Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Design Therapeutics	N/A	-18.01%	-17.38%
Immix Biopharma	N/A	-102.68%	-80.89%

Do insiders and institutionals hold more shares of DSGN or IMMX?

56.6% of Design Therapeutics shares are held by institutional investors. Comparatively, 11.3% of Immix Biopharma shares are held by institutional investors. 31.2% of Design Therapeutics shares are held by insiders. Comparatively, 48.9% of Immix Biopharma shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Does the MarketBeat Community favor DSGN or IMMX?

Design Therapeutics and Immix Biopharma both received 10 outperform votes by MarketBeat users. However, 100.00% of users gave Immix Biopharma an outperform vote while only 33.33% of users gave Design Therapeutics an outperform vote.

Company	Underperform	Outperform
Design Therapeutics	Outperform Votes 10 33.33%	Underperform Votes 20 66.67%
Immix Biopharma	Outperform Votes 10 100.00%	Underperform Votes No Votes

Do analysts rate DSGN or IMMX?

Design Therapeutics presently has a consensus target price of $7.00, indicating a potential upside of 38.34%. Immix Biopharma has a consensus target price of $7.00, indicating a potential upside of 243.14%. Given Immix Biopharma's stronger consensus rating and higher possible upside, analysts plainly believe Immix Biopharma is more favorable than Design Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Design Therapeutics	0 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.33
Immix Biopharma	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Summary

Immix Biopharma beats Design Therapeutics on 7 of the 13 factors compared between the two stocks.